Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?

Immunopharmacology and Immunotoxicology

Volumn 33, Issue 4, 2011, Pages 744-750

  Gluhovschi, Cristina ^a   Gadalean, Florica ^a   Kaycsa, Adriana ^a   Curescu, Manuela ^a   Sporea, Ioan ^a   Gluhovschi, Gheorghe ^a   Petrica, Ligia ^a   Velciov, Silvia ^a   Bozdog, Gheorghe ^a   Bob, Flaviu ^a   Vernic, Corina ^a   Cioca, Daniel ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Enzymes; HBV hepatitis; HCV hepatitis; Interferon

Indexed keywords

ADEFOVIR; ALBUMIN; ALPHA 1 MICROGLOBULIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; CREATININE; ENTECAVIR; LAMIVUDINE; N ACETYL BETA GLUCOSAMINIDASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALBUMIN URINE LEVEL; ALBUMINURIA; ANTIVIRAL THERAPY; ARTICLE; COLORIMETRY; CREATININE BLOOD LEVEL; DELTA AGENT HEPATITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SIDE EFFECT; TREATMENT DURATION;

ADENINE; ADULT; ALBUMINURIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 80755143894     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2010.551129     Document Type: Article

References (38)

1. Burra, P. Hepatitis C. Semin Liver Dis 2009, 29, 53-65.
2. Samuel, C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001, 14, 778-809, table of contents. (Pubitemid 32979631)
3. Durlik, M., Gaciong, Z., Rancewicz, Z., Rowinska, D., Wyzgal, J., Kozlowska, B., Gradowska, L., Lao, M., Nowaczyk, M., Korczak- Kowalska, G. Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha. Transplant Proc 1995, 27, 958-959.
4. Kovarik, J., Mayer, G., Pohanka, E., Schwarz, M., Traindl, O., Graf, H., Smolen, J. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988, 45, 402-405. (Pubitemid 18084684)
5. Rostaing, L., Izopet, J., Baron, E., Duffaut, M., Puel, J., Durand, D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995, 59, 1426-1431.
6. Magnone, M., Holley, J.L., Shapiro, R., Scantlebury, V., McCauley, J., Jordan, M., Vivas, C., Starzl, T., Johnson, J.P. Interferon-alphainduced acute renal allograft rejection. Transplantation 1995, 59, 1068-1070.
7. Willson, R.A. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 2002, 35, 89-92. (Pubitemid 34663358)
8. Fried, M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36, S237-S244. (Pubitemid 35253486)
9. Okushin, H., Morii, K., Uesaka, K., Yuasa, S. Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C. World J Hepatol 2010, 2, 226-232.
10. Markowitz, G.S., Nasr, S.H., Stokes, M.B., D'Agati, V.D. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5, 607-615.
11. Kurschel, E., Metz-Kurschel, U., Hofmann, W., Niederle, N. Detection of nephrotoxicity of human alpha 2b interferon with special reference to the analysis of urine enzymes in patients with chronic myeloid leukemia. Klin Wochenschr 1987, 65, 667-672. (Pubitemid 17099943)
12. Kurschel, E., Metz-Kurschel, U., Niederle, N., Aulbert, E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail 1991, 13, 87-93.
13. Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Heinzen, E.L., Qiu, P., Bertelsen, A.H., Muir, A.J., Sulkowski, M., McHutchison, J.G., Goldstein, D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461, 399-401.
14. Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E., Borovicka, J., Colombo, S., Cerny, A., Dufour, J.F., Furrer, H., Günthard, H.F., Heim, M., Hirschel, B., Malinverni, R., Moradpour, D., Müllhaupt, B., Witteck, A., Beckmann, J.S., Berg, T., Bergmann, S., Negro, F., Telenti, A., Bochud, P.Y.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138, 1338-45, 1345.e1.
15. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., Bassendine, M., Spengler, U., Dore, G.J., Powell, E., Riordan, S., Sheridan, D., Smedile, A., Fragomeli, V., Müller, T., Bahlo, M., Stewart, G.J., Booth, D.R., George, J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41, 1100-1104.
16. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., Ito, Y., Mita, E., Tanaka, E., Mochida, S., Murawaki, Y., Honda, M., Sakai, A., Hiasa, Y., Nishiguchi, S., Koike, A., Sakaida, I., Imamura, M. Ito, K., Yano, K., Masaki, N., Sugauchi, F., Izumi, N., Tokunaga, K., Mizokami, M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41, 1105-1109.
17. Bihl F., Pache I., Hess J., Moradpour D. Le point sur le traitement de lh̀epatite C chronique. Revue Medicale Suisse 2010, 6, 174-179.
18. Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.P., Bourlière, M., Gharakhanian, S., Bengtsson, L., McNair, L., George, S., Kieffer, T., Kwong, A., Kauffman, R.S., Alam, J., Pawlotsky, J.M., Zeuzem, S.; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360, 1839-1850.
19. Kwo P., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., Davis M., Galati J., Gordon S.C., Ravendhran N., Rossaro L., Anderson F.H., Jacobson I.M., Rubin R., Koury K., Pedicone L., Chaudri E., Albrecht J.K. HCV SPRINT-I final results: SVR 24 from a phase 2 study of boceprevir plus peginterferon-alpha2b/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C. J Hepatol 2009, 50(Suppl I), S4.
20. McHutchison, J.G., Everson, G.T., Gordon, S.C., Jacobson, I.M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., Muir, A.J.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360, 1827-1838.
21. Kotenko, S.V., Gallagher, G., Baurin, V.V., Lewis-Antes, A., Shen, M., Shah, N.K., Langer, J.A., Sheikh, F., Dickensheets, H., Donnelly, R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4, 69-77. (Pubitemid 36109115)
22. Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T.E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., Ostrander, C., Dong, D., Shin, J., Presnell, S., Fox, B., Haldeman, B., Cooper, E., Taft, D., Gilbert, T., Grant, F.J., Tackett, M., Krivan, W., McKnight, G., Clegg, C., Foster, D., Klucher, K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4, 63-68. (Pubitemid 36104710)
23. Shiffman M.L., Lawitz E.J., Zaman A., Vierling J., Yoffe B., Freeman J. PEG-IFN-?: Antiviral activity and safety profile in a 4-week phase I b study in relapsed genotype 1 hepatitis C virus infection. J Hepatol 2009, 50, S237.
24. Doerig C., Antonino A., Pache I., Moradpour D. Prise en charge de lh̀epatite B chronique: un defi en evolution constante. Revue Medicale Suisse 2010, 6, 168-173.
25. Izzedine, H., Launay-Vacher, V., Deray, G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005, 45, 804-817. (Pubitemid 43181039)
26. Perazella, M.A. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 2010, 78, 1060-1063.
27. Herlitz, L.C., Mohan, S., Stokes, M.B., Radhakrishnan, J., D'Agati, V.D., Markowitz, G.S. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010, 78, 1171-1177.
28. Swan S.K., Olyaei A., Sica D. Syllabus: Clinical Pharmacology for the Nephrologist. NephSAP 2010, 9, 230-233.
29. Harris, J.M., Martin, N.E., Modi, M. Pegylation: a novel process or modifying pharmacokinetics. Clin Pharmacokinet 2001, 40,539-551. (Pubitemid 32738660)
30. Zeuzem, S. Do differences in pegylation of interferon alfa matter? astroenterology 2010, 138, 34-36.
31. Zeuzem, S., Welsch, C., Herrmann, E. Pharmacokinetics of eginterferons. Semin Liver Dis 2003, 23 Suppl 1, 23-28.
32. Bonventre, J.V., Vaidya, V.S., Schmouder, R., Feig, P., Dieterle, F. ext-generation biomarkers for detecting kidney toxicity. Nat iotechnol 2010, 28, 436-440.
33. Russo, L.M., Sandoval, R.M., McKee, M., Osicka, T.M., Collins, A.B., Brown, D., Molitoris, B.A., Comper, W.D. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007, 71, 504-513. (Pubitemid 46398675)
34. Russo, L.M., Sandoval, R.M., Campos, S.B., Molitoris, B.A., Comper, W.D., Brown, D. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009, 20, 489-494.
35. Grubb A., Lindstrom V., Kristensen K. Filtration quality: a new measure of renal disease. Clin Chem Lab Med 2007, 45, S273-S274.
36. Yu, H., Yanagisawa, Y., Forbes, M.A., Cooper, E.H., Crockson, R.A., MacLennan, I.C. Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol 1983, 36, 253-259. (Pubitemid 13160686)
37. Palmieri, L., Ronca, G., Cioni, L., Puccini, R. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-betaglucosaminidase, alanine aminopeptidase and lysozyme in patients with renal disease. Contrib Nephrol 1984, 42, 123-129.
38. Tanji, N., Tanji, K., Kambham, N., Markowitz, G.S., Bell, A., D'agati, V.D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001, 32, 734-740. (Pubitemid 32726898)